Health & Fitness
Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Mon, February 7, 2011Tornier to Highlight Six New Products at American Academy of Orthopaedic Surgeons (AAOS) Meeting
Published in Health and Fitness on Tuesday, February 15th 2011 at 12:25 GMT by Market Wire
EDINA, Minn.--([ BUSINESS WIRE ])--Tornier N.V. (NASDAQ: TRNX), a global leader in extremity orthopaedics, today announced it will highlight six new products at the American Academy of Orthopaedic Surgeons 2011 Annual Meeting (aAAOSa) being held February 15-19 in San Diego, CA. The six new Tornier products address a range of joint replacement, joint repair, and soft tissue repair needs of upper and lower extremity specialist surgeons and their patients.
Doug Kohrs, President and CEO of Tornier, commented, aAt this yeara™s AAOS, we are introducing six new products featuring innovative designs and materials, not just modifications of existing products. All of our extremity products and surgical techniques are developed in close collaboration with specialists on the leading edge of surgical science who are committed to addressing the clinical needs of their patients.a
The Ascenda" Shoulder is a bone-sparing implant system that incorporates a ashort stema that has been designed to match the internal contours of the humerus, minimize bone removal, and avoid the disruption of tendons that are vital to shoulder joint function. The Ascend Shoulder is available both in the United States and Europe.
The Simplicitia" Shoulder is an innovative new implant system that is based on a astem-lessa design. The Simpliciti is approved for use in Europe, and is an investigational device in the United States. The Simpliciti clinical trial is one of the first FDA-regulated clinical studies conducted in the United States for a shoulder arthroplasty system.
The InSpyrea" Shoulder is a minimally invasive shoulder implant based on Torniera™s pyrocarbon material technology. A spherical, stemless design, the InSpyre prosthesis is a single component system requiring no glenoid implant due to the unique soft tissue compatibility of the companya™s pyrocarbon technology that is characterized by favorable implant-on-bone and implant-on-soft tissue fatigue and wear characteristics. The InSpyre shoulder implant is currently available for sale in Europe and is not approved for sale in the United States.
The Stabilisa" Ankle Fusion System provides surgeons with multiple plating options to stabilize the ankle joint for fusion procedures. The plating options allow for either anterior or lateral surgical approaches and include advanced instrumentation featuring controlled distraction and compression, as well as unique cutting guides that reduce variability in joint positioning. The Stabilis system also incorporates Torniera™s patented Coverloca" technology which reduces screw prominence and allows for plate compression to the bone. The Stabilis is available in the United States.
The Wavea" Calcaneal Fracture Plate is the first such system to allow for a less invasive approach compared to a traditionally large aLa flap incision. By reducing the incision for calcaneal fracture repair, wound healing complication risks are reduced. The Wave Plate also matches the complex geometry of the calcaneus, which aids in the restoration of the bonea™s height, length and width. The Wave is available in the United States.
The 2.8 Pitona" Soft Tissue FixationImplant is an innovative new anchoring device for the secure reattachment of soft tissue to bone. Its small, minimally invasive insertion footprint and unique laser markings make it ideal for the arthroscopic treatment of challenging rotator cuff tears, with minimal disruption to either tendon or bone. The 2.8 Piton is available in the United States and Europe.
Also during this yeara™s AAOS Meeting, Tornier will highlight new arthroscopic techniques for rotator cuff repair with biologic reinforcement grafts. Working with a team of sports medicine surgeons, Tornier has developed several efficient techniques to deploy its Conexaa" Reconstructive Tissue Matrix using Torniera™s proprietary Piton anchors, as well as its minimally invasive ArthroTunnelera" anchorless rotator cuff repair system. The Piton, ArthroTunneler, and Conexa are available in the United States and Europe.
About Tornier
Tornier N.V. is a global medical device company focused on serving extremities specialists that treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The companya™s broad offering of over 70 product lines includes joint replacement, trauma, sports medicine, and orthobiologic products to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Torniera™s aSpecialists Serving Specialistsa philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world. For more information regarding Tornier, visit [ www.tornier.com ].
Safe Harbor Statement
This Press Release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this Press Release include the intent, belief or current expectations of the Company and members of its management team with respect to the Companya™s future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, the Companya™s ability to successfully integrate, achieve and capitalize on its new products. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can also be found in the Companya™s Risk Factor disclosures in its Registration Statement on Form S-1, as amended, initially filed with the Securities and Exchange Commission on June 8, 2010. The Company disclaims any responsibility to update any forward-looking statements.
